{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:41:48Z","timestamp":1790361708819,"version":"4.1.0"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Radiation therapy (RT) for Hodgkin lymphoma has changed dramatically over the past couple of decades, from the very large extended-field RT with prophylactic treatment of all the major lymph node regions to the very limited involved-site RT with treatment only of the initially macroscopically involved lymphoma volume in the combined modality setting. Technological developments in imaging, treatment planning, and treatment machines have enabled very significant reductions in radiation doses to normal organs without jeopardizing the coverage of the lymphoma. Hence, the risks of long-term adverse effects have become much smaller than those in the past. Radiation therapy for Hodgkin lymphoma is now a highly individualized treatment, tailored to each patient. The risks of this limited RT should be weighed against the risks of long-term toxicity of possible additional systemic treatment up-front and at relapse in order to select the optimal treatment combination for each individual patient.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000332","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:55:42Z","timestamp":1538646942000},"page":"237-243","source":"Crossref","is-referenced-by-count":18,"title":["Radiotherapy for Hodgkin Lymphoma"],"prefix":"10.1097","volume":"24","author":[{"given":"Lena","family":"Specht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","first-page":"166","article-title":"Cases of sarcoma and of Hodgkin's disease treated by exposures to x-rays\u2014a preliminary report","volume":"38","year":"1902","journal-title":"JAMA"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","year":"2007","journal-title":"Blood"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib6-20230924","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","year":"2002","journal-title":"Blood"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","volume":"20","year":"2002","journal-title":"J Clin Oncol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.1998.16.3.830","article-title":"Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10147-015-0863-y","article-title":"The concept and evolution of involved site radiation therapy for lymphoma","volume":"20","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ijrobp.2011.09.020","article-title":"Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma","volume":"83","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.radonc.2013.09.027","article-title":"Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy","volume":"110","year":"2014","journal-title":"Radiother Oncol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijrobp.2013.06.004","article-title":"Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?","volume":"87","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","year":"2013","journal-title":"Ann Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ijrobp.2014.06.069","article-title":"A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: what can we learn?","volume":"90","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/pbc.24861","article-title":"The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma","volume":"61","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","year":"2015","journal-title":"Lancet Haematol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijrobp.2017.09.048","article-title":"Reduced mortality risk in the recent era in early-stage Hodgkin lymphoma patients treated with radiation therapy with or without chemotherapy","volume":"100","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma","volume":"97","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions","volume":"24","year":"2013","journal-title":"Ann Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.10.018","article-title":"Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease","volume":"78","year":"2006","journal-title":"Radiother Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","year":"2006","journal-title":"Radiother Oncol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/annonc\/mdr439","article-title":"Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy","volume":"23","year":"2012","journal-title":"Ann Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2011.05.054","article-title":"Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy","volume":"83","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma","volume":"85","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","year":"2005","journal-title":"Ann Oncol"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","year":"2005","journal-title":"Cancer"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","year":"2003","journal-title":"N Engl J Med"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2006.08.041","article-title":"Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma","volume":"67","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"bib39-20230924","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","year":"2006","journal-title":"Haematologica"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.radonc.2017.05.014","article-title":"Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a pre-chemotherapy PET-CT in the radiotherapy treatment position","volume":"124","year":"2017","journal-title":"Radiother Oncol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2007.07.003","article-title":"Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?","volume":"85","year":"2007","journal-title":"Radiother Oncol"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2014.04.026","article-title":"Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients","volume":"89","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2006.00802.x","article-title":"Clinical impact of FDG-PET\/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma","volume":"78","year":"2007","journal-title":"Eur J Haematol"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2004.07.029","article-title":"Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma","volume":"73","year":"2004","journal-title":"Radiother Oncol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.semnuclmed.2017.09.006","article-title":"PET\/CT in radiation therapy planning","volume":"48","year":"2018","journal-title":"Semin Nucl Med"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijrobp.2010.06.044","article-title":"[18F]FDG\u2013positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies","volume":"81","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijrobp.2014.02.006","article-title":"A prospective study of (1)(8)FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies","volume":"89","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines","volume":"88","year":"2008","journal-title":"Radiother Oncol"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/0284186X.2017.1279750","article-title":"Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group","volume":"56","year":"2017","journal-title":"Acta Oncol"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijrobp.2014.12.009","article-title":"Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma","volume":"9","year":"2014","journal-title":"Radiat Oncol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ijrobp.2008.12.048","article-title":"Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy","volume":"75","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijrobp.2015.09.043","article-title":"In the battle between protons and photons for hematologic malignancies, the patient must win","volume":"95","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/PPO.0000000000000076","article-title":"Proton therapy in the management of lymphoma","volume":"20","year":"2014","journal-title":"Cancer J"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3109\/10428194.2010.493250","article-title":"Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma","volume":"51","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"bib57-20230924","first-page":"456","article-title":"Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy","volume":"26","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2011.06.1959","article-title":"Consolidative involved-node proton therapy for stage IA\u2013IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study","volume":"83","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2010.05.007","article-title":"Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma","volume":"81","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/annonc\/mdx356","article-title":"Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3109\/10428194.2014.975802","article-title":"Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"bib63-20230924","article-title":"Proton therapy for the management of Hodgkin and non-Hodgkin lymphomas involving the mediastinum: guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","year":"2018","journal-title":"Blood (in press)"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/1097-0142(19870915)60:6<1232::AID-CNCR2820600612>3.0.CO;2-F","article-title":"The effect of the respiratory cycle on mediastinal and lung dimensions in Hodgkin's disease. Implications for radiotherapy gated to respiration","volume":"60","year":"1987","journal-title":"Cancer"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma","volume":"82","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","article-title":"Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold","volume":"54","year":"2015","journal-title":"Acta Oncol"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2013.10.028","article-title":"Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma","volume":"88","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:11:37Z","timestamp":1695532297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00006"}},"subtitle":["Reducing Toxicity While Maintaining Efficacy"],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000332","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}